Increased levels of platelets and endothelial-derived microparticles in patients with non-valvular atrial fibrillation during rivaroxaban therapy
| Autor: | Magdalena Kaźnica-Wiatr, Leszek Drabik, Lidia Tomkiewicz-Pająk, Maria Olszowska, Piotr Podolec, Aleksandra Lenart-Migdalska |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Blood Platelets
Male medicine.medical_specialty CD42b endothelial-derived microparticles Non valvular atrial fibrillation 030204 cardiovascular system & hematology Atrial thrombosis 03 medical and health sciences 0302 clinical medicine platelet-derived microparticles Rivaroxaban Cell-Derived Microparticles Risk Factors Internal medicine Atrial Fibrillation medicine Humans Diseases of the circulatory (Cardiovascular) system Platelet In patient Aged 030304 developmental biology 0303 health sciences business.industry nonvalvular atrial fibrillation Endothelial Cells Atrial fibrillation Hematology General Medicine Middle Aged medicine.disease Anticoagulant therapy RC666-701 Cardiology Original Article Female CD144 Statin therapy business medicine.drug |
| Zdroj: | Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021) Clinical and Applied Thrombosis/Hemostasis |
| Popis: | It is known that atrial fibrillation (AF) is associated with the procoagulant state. Several studies have reported an increase of circulating microparticles in AF, which may be linked to a hypercoagulable state, atrial thrombosis and thromboembolism. We evaluated in our study alterations in both platelet (PMP, CD42b) and endothelial-derived (EMP, CD144) microparticle levels on anticoagulant therapy with rivaroxaban in nonvalvular AF. After administration of rivaroxaban, PMP levels were increased (median, [IQR] 35.7 [28.8-47.3] vs. 48.4 [30.9-82.8] cells/µL; P = 0.012), along with an increase in EMP levels (14.6 [10.0-18.6] vs. 18.3 [12.9-37.1] cells/µL, P < 0.001). In the multivariable regression analysis, the independent predictor of post-dose change in PMPs was statin therapy (HR −0.43; 95% CI −0.75,−0.10, P = 0.011). The post-dose change in EMPs was also predicted by statin therapy (HR −0.34; 95% CI −0.69, −0.01, P = 0.046). This study showed an increase in both EMPs and PMPs at the peak plasma concentration of rivaroxaban. Statins have promising potential in the prevention of rivaroxaban-related PMP and EMP release. The pro-thrombotic role of PMPs and EMPs during rivaroxaban therapy requires further study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|